Seagen’s Adcetris combo appears well-tolerated in Phase 2 trial of cHL patients
In the trial, 150 patients out of 154 patients with early-stage disease showed a 98% overall response rate…
We use them to give you the best experience. If you continue using our website, we'll assume that you are happy to receive all cookies on this website.
ContinueLearn More X
14 Jun 23
In the trial, 150 patients out of 154 patients with early-stage disease showed a 98% overall response rate…
14 Jun 23
Company expanding from AI-powered Data Verification Tool to ‘complete submission’ data platform
14 Jun 23
Venlo, the Netherlands, and Redwood City, California, June13, 2023 (GLOBE NEWSWIRE) -- QIAGEN (NYSE: QGEN; Frankfurt Prime Standard:…
13 Jun 23
The FDA approval is based on the findings from a Phase 3 trial which showed a statistically significant…
13 Jun 23
The approval will enable the Swiss company to scale up its drug substance manufacturing process for ADSTILADRIN at…
13 Jun 23
Under the partnership, Curigin will use Charles River's expertise in contract development and manufacturing organisation solutions for supporting…
13 Jun 23
Product eliminates the need for two discrete syringe preparations and administrations, which helps increase efficiency for hospitals and…
12 Jun 23
The deal will give Novartis two late-stage medicines for the treatment of IgA nephropathy in the form of…
12 Jun 23
The panel’s backing was based on the sBLA, which includes findings from Eisai’s global confirmatory Phase 3 Clarity…
12 Jun 23
The new platform is designed to enable the end-to-end analysis and clinical reporting of nanopore sequencing, empowering clinical…